Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs (950130) Price & Analysis

― Followers

950130 Stock Chart & Stats

₩2195.00

-₩85.00(-3.73%)

Aug 19, 2026

―

Day’s Range― - ―

52-Week Range₩1,945.00 - ₩5,355.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)64.94K

Market Cap

₩80.20B

Enterprise Value-₩151.80K

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.12

Next Earnings

Nov 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1095.79

Shares Outstanding35,173,836

10 Day Avg. Volume49,245

30 Day Avg. Volume64,941

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

950130 FAQ

What was Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs’s price range in the past 12 months?

Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs lowest stock price was ₩1945.00 and its highest was ₩5355.00 in the past 12 months.

What is Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs’s market cap?

Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs’s market cap is ₩80.20B.

When is Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs’s upcoming earnings report date?

Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs’s upcoming earnings report date is Nov 12, 2026 which is in 83 days.

How were Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs’s earnings last quarter?

Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs released its earnings results on Aug 18, 2026. The company reported -₩1095.793 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs overvalued?

According to Wall Street analysts Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs pay dividends?

Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs pays a N/A dividend of ₩871 which represents an annual dividend yield of N/A. See more information on Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs dividends here

What is Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs’s EPS estimate?

Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs have?

Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs has 35,173,836 shares outstanding.

What happened to Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs’s price movement after its last earnings report?

Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs reported an EPS of -₩1095.793 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.299%.

Which hedge fund is a major shareholder of Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs?

Currently, no hedge funds are holding shares in KR:950130

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs

Access Bio Inc., a U.S.-based biotechnology firm, specializes in the research, development, and manufacturing of advanced in vitro rapid diagnostic tests, biosensors, and molecular diagnostic solutions. These offerings are designed primarily for the prompt identification and prevention of infectious diseases. The company's core technological expertise spans immunochemical, biochemical, and molecular in vitro diagnostics. Among its diverse product range are rapid diagnostic tests like CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM. Their biosensor line features the CareStart G6PD Biosensor, while their molecular diagnostics portfolio includes CareStart HPV and CareStart CAH.